EMERGENT BIOSOLUTIONS INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
EMERGENT BIOSOLUTIONS INC. (EBS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $10.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2020-02-25
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2019-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2019-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2019-06-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2019-03-31 was $10.00M.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2019 was $10.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | $0.00 derived: sum of 3 quarters · filed 2020-02-25 | $10.00M 10-K · filed 2020-02-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $10.00M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $10.00M 10-Q · filed 2019-08-02 | ||
| 2019-03-31 | $10.00M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |